Trial reportThe American journal of tropical medicine and hygiene2018
Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.
Trial report in The American journal of tropical medicine and hygiene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Safety and Immunogenicity of an AS03The American journal of tropical medicine and hygiene · 2020Trial
- Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study.The American journal of tropical medicine and hygiene · 2020Trial
- Targeting dengue through mucosal vaccination: the potential of NS1 and bacterial spore-based delivery platforms.Frontiers in immunology · 2026Review
- Update on efficacy, safety, and immunogenicity of Dengue vaccines: a systematic review and meta-analysis.Le infezioni in medicina · 2026Review
- Dengue Vaccines.Current topics in microbiology and immunology · 2026Review
- State of the Art on Vaccine Development Against Dengue Infection: Scoping Review of the Literature.Infectious disease reports · 2025Review
- Nano-interventions for dengue: a comprehensive review of control, detection and treatment strategies.Inflammopharmacology · 2025Review
- Advancements in dengue vaccines: A historical overview and pro-spects for following next-generation candidates.Journal of microbiology (Seoul, Korea) · 2025Review
- Mature dengue virus particles inactivated by a non-ionic detergent retain quaternary neutralizing epitopes and induce potent neutralizing antibodies.Frontiers in immunology · 2025Article
- Current status of the development of dengue vaccines.Vaccine: X · 2025Review
- Opportunities and challenges of mRNA technologies in development of dengue virus vaccine.Frontiers in immunology · 2025Review
- Dengue fever in hyperglycemic patients: an emerging public health concern demanding eyes on the effective management strategies.Health science reports · 2024Article
- Article
- Approaches of dengue control: vaccine strategies and future aspects.Frontiers in immunology · 2024Review
- Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art.The Journal of general virology · 2023Review
- Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults.NPJ vaccines · 2022Article
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice.Microorganisms · 2022Article
- Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?Frontiers in medical technology · 2021Review
- Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection.EBioMedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
Abstract
The safety and immunogenicity of four adjuvanted formulations of an investigational tetravalent dengue purified inactivated vaccine (DPIV) were evaluated in a predominantly dengue-primed population in Puerto Rico. In this placebo-controlled, randomized, observer-blind, phase I trial, 100 healthy adults were randomized 1:1:1:1:1 to receive DPIV at Day (D)0 and D28 (1 μg per dengue virus [DENV] type 1-4 adjuvanted with either alum, AS01
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.